Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SMStefano MolicaDADavid Allsup

Discussion

Loading...

Member takes

Overview

Indirect analysis reveals no significant difference in progression-free survival among CLL treatment methods, implying flexible selection based on patient factors.

Key Points

  • This research aims to compare treatment efficacy of BTK inhibitors and venetoclax-based therapies in CLL across IGHV subgroups.
  • Conducted an indirect comparative analysis of treatment outcomes from phase III trials
  • Evaluated continuous BTK inhibitor therapies and time-limited venetoclax-BTKi regimens
  • Used individual patient data to assess progression-free survival (PFS) over four years
  • No significant difference in four-year PFS among treatment groups
  • Progression-free survival was similar regardless of IGHV mutation status
  • Findings suggest treatment personalization based on patient factors can maintain efficacy.

Cite This Study

Molica et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d870https://doi.org/10.1182/blood-2025-3887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  2. 2Real-world outcomes of bruton tyrosine kinase inhibitors versus venetoclax in chronic lymphocytic leukemia.2026
  3. 3Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  4. 4Real-world overall survival outcomes of BTK inhibitors vs. venetoclax-based therapy as second-line treatment for chronic lymphocytic leukemia.2026
  5. 5Long-term outcomes in high-risk patients with chronic lymphocytic leukemia treated with targeted therapies in the real-world2025